论文部分内容阅读
目的 提高人脑胶质瘤过继免疫治疗的效果 ,探索治疗脑胶质瘤的新途径。方法 用CD3和rIL - 2共同诱导人外周血单个核细胞 ,诱导、扩增新型抗胶质瘤效应细胞CD3AK细胞 ,并与LAK细胞在某些生物学方面进行了比较。结果 两组效应细胞增殖曲线均于第 6天达高峰 ,峰值可见 ,CD3AK细胞 >LAK细胞 (P <0 0 5 ) ;CD3AK细胞扩增倍数明显高于LAK细胞 (P <0 0 5 ) ;两组效应细胞于培养的第 6、 8、 10天所测得的杀伤胶质瘤细胞BT32 5活性可见 ,CD3AK细胞 >LAK细胞 (P <0 0 5或P <0 0 1)。结论 CD3和rIL - 2具有协同增强作用 ,使CD3A细胞成为较LAK细胞增殖能力、杀伤活性更强的免疫效应细胞 ,且rIL - 2用量减少 ,有胶质瘤的过继免疫治疗打下了理论基础
Objective To improve the effect of adoptive immunotherapy in human glioma and explore new ways to treat glioma. Methods CD3 and rIL - 2 were used to induce human peripheral blood mononuclear cells (PBMCs) to induce and amplify a novel anti - glioma effector CD3AK cell line, which was compared with that of LAK cells in some aspects of biology. Results The proliferative curve of effector cells in both groups reached their peak on the 6th day. The peak value of CD3AK cells> LAK cells (P <0 05) and the multiplication of CD3AK cells was significantly higher than that of LAK cells (P <0 05) The activity of BT32 5 of the group of killer glioma cells measured on day 6, day 8, and day 10 of culture group was higher than that of the group of CD3AK cells> LAK cells (P <0.05 or P <0.01). Conclusions CD3 and rIL - 2 have a synergistic enhancement effect, making CD3A cells an immunocompetent cell with stronger proliferative ability and killing activity than LAK cells, and the dosage of rIL - 2 is reduced and the theory of adoptive immunotherapy of gliomas is laid down.